news
Inovio initiates Phase I trial of its Ebola DNA immunotherapy
12 May 2015 | By Victoria White
Inovio Pharmaceuticals has initiated a Phase I trial to evaluate safety, tolerability and immune responses of its Ebola DNA immunotherapy...
List view / Grid view
Drug delivery
news
Nabriva Therapeutics presents data on lefamulin at ECCMID 2015
27 April 2015 | By Victoria White
Three posters on the Extended Spectrum Pleuromutilins (ESP) Programme and one poster on lefamulin were presented at ECCMID 2015...
article
Issue #2 2015 – Digital edition
In Issue #2 2015: Outsourcing, Drug pricing reforms, Stem Cells in-depth focus, Microbiology series, Environmental monitoring, LC-MS in-depth focus, Manufacturing solutions, PAT series and much more...
news
First patient dosed in Phase 1 trial of CM-24, a novel immune checkpoint inhibitor for cancer immunotherapy
20 April 2015 | By Victoria White
The first patient has been dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory mAb for the treatment of various types of cancers...
news
Inovio’s INO-3112 DNA immunotherapy shows positive preliminary results
9 April 2015 | By Victoria White
INO-3112 DNA immunotherapy has generated strong T cell responses in patients with head and neck cancer associated with human papillomavirus (HPV)...
news
Simple antibiotic strategy is sufficient for treating pneumonia
7 April 2015 | By Victoria White
Patients with pneumonia can initially be treated with most common antibiotics, according to research carried out by University Medical Centre Utrecht...
news
Stallergenes announces the approval in Japan of STG320, the first sublingual immunotherapy tablet for the treatment of house dust mite allergy
30 March 2015 | By Victoria White
Stallergenes has announced that its partner, Shionogi & Co., Ltd has received the approval of STG320 from the Japanese health authorities...
news
Antibiotics pipeline boasts 741 products, but first-in-class development remains low, says GBI Research
27 March 2015 | By Victoria White
While antibiotics boast a vast pipeline, the majority is dominated by generics, as weak financial incentives and high fail rates have discouraged innovation..
news
Scientists called to reduce antibiotic use in experiments
20 March 2015 | By Victoria White
Scientists should reduce antibiotic use in lab experiments - according to a researcher from UEA’s Norwich Medical School...
article
Issue #1 2015 – Digital edition
In Issue #1 2015: Regulatory Insight, Biologics, NIR in-depth focus, Raman in-depth focus, PAT, Drug Delivery, Microbiology Series and much more...
article
Evaluating inhaler performance using idealised throats
10 March 2015 | By Andrew R. Martin and Warren H. Finlay, University of Alberta
The development of orally-inhaled drug products is a complex endeavour spanning multiple technical and medical fields. For the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), the inhalation delivery route permits the drug to be directly targeted to the afflicted organ, namely the lung. As…
news
AYOXXA and SERI to collaborate on protein biomarker detection
3 February 2015 | By AYOXXA Biosystems / SERI
AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic diagnostic tools...
news
FDA grants Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A
2 February 2015 | By Roche
US FDA has granted Breakthrough Therapy Designation for Roche’s investigational cancer immunotherapy MPDL3280A (anti-PDL1) in non-small cell lung cancer...
news
Nabriva Therapeutics strengthens Board and Management Team
30 January 2015 | By Nabriva Therapeutics AG
Nabriva Therapeutics AG announced the appointment of Charles Rowland to the Nabriva Supervisory Board...
article
Issue #6 2014 – Digital edition
In Issue #6 2014: Polymerase Chain Reaction, Imaging, PAT in-depth focus, Screening in-depth focus, Microbiology Series and much more...
